ロード中...
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
BACKGROUND: The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with chronic migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in this study was flexible from 155 U to 195 U at the physician’s discretion. Therefore, the objective of this prospective study...
保存先:
| 出版年: | J Headache Pain |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Milan
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4720620/ https://ncbi.nlm.nih.gov/pubmed/26792662 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10194-016-0591-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|